Matching trials
2,411 results
- DEFEAT-AKIIndependent statistical analysis of Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04633889).
- Defibrotide TMA Prophylaxis Pilot Trial: Complete Statistical AnalysisIndependent statistical analysis of Defibrotide TMA Prophylaxis Pilot Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03384693).
- Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases: Complete Statistical AnalysisIndependent statistical analysis of Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases: primary endpoint results, effect estimate…
- Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates: Complete Statistical AnalysisIndependent statistical analysis of Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00986947).
- DESTINY-Breast07Independent statistical analysis of DESTINY-Breast07, a phase 1/2 randomized study of trastuzumab deruxtecan combinations in HER2-positive metastatic breast cancer, including trial design, registered endpoints, planned statistical analysis, and interpretation.
- DESTINY-CRC01Independent statistical analysis of DESTINY-CRC01, a phase 2 sequential study of DS-8201a in HER2-expressing advanced colorectal cancer, including trial design, response endpoints, planned statistical interpretation, and safety.
- DESTINY-CRC02Independent statistical analysis of DESTINY-CRC02, a randomized phase 2 trial of trastuzumab deruxtecan in participants with HER2-overexpressing advanced or metastatic colorectal cancer, including its design, objective response endpoint, statistical methodology, safety, and…
- DESTINY-Gastric02A detailed statistical analysis and educational interpretation of DESTINY-Gastric02, a phase 2 single-group trial of trastuzumab deruxtecan in HER2-positive unresectable or metastatic gastric or gastro-esophageal junction adenocarcinoma.
- DESTINY-PanTumor02A detailed statistical analysis of DESTINY-PanTumor02, a phase 2 non-randomized study of trastuzumab deruxtecan in patients with selected HER2-expressing tumors, including trial design, objective response rate methodology, planned analysis, and statistical interpretation.
- Developing and Testing a Comprehensive MS Spasticity Management Program: Complete Statistical AnalysisIndependent statistical analysis of Developing and Testing a Comprehensive MS Spasticity Management Program: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02170779).
- Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Development of Vitamin D as a Therapy for Breast Cancer – Phase 2: Complete Statistical AnalysisIndependent statistical analysis of Development of Vitamin D as a Therapy for Breast Cancer - Phase 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- DEVILIndependent statistical analysis of Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- DEX-TRA 02Independent statistical analysis of Analgesic Effect of Different Combinations of Dexketoprofen Trometamol With Tramadol Hydrochloride in a Model of Moderate to Severe Pain: primary endpoint results, effect estimate with confidence interval, sample-size…
- Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal: Complete Statistical AnalysisIndependent statistical analysis of Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04470050).
- DFA-02 in Patients Undergoing Colorectal Surgery: Complete Statistical AnalysisIndependent statistical analysis of DFA-02 in Patients Undergoing Colorectal Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01496352).
- DHT-3Independent statistical analysis of Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3]: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00490022).
- Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Dietary Nitrate for Heart Failure: Complete Statistical AnalysisIndependent statistical analysis of Dietary Nitrate for Heart Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01682356).
- Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01165996).
- Dimethyl Fumarate for Obstructive Sleep Apnea: Complete Statistical AnalysisIndependent statistical analysis of Dimethyl Fumarate for Obstructive Sleep Apnea: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02438137).
- DIPIndependent statistical analysis of Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Discontinuing NSAIDs in Veterans With Knee Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Discontinuing NSAIDs in Veterans With Knee Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01799213).
- DIVERTIndependent statistical analysis of Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- DOAC LVADIndependent statistical analysis of Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- DOC-MEKIndependent statistical analysis of Docetaxel With or Without AZD6244 in Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01256359).
- Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer: primary endpoint results, effect estimate with confidence interval,…
- Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway: primary endpoint results, effect estimate with confidence interval,…
- Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01382706).
- Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck: primary endpoint results, effect estimate with confidence interval,…
- Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency: primary endpoint results, effect estimate with confidence interval,…
- Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval,…
- Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene: Complete Statistical AnalysisIndependent statistical analysis of Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval,…
- Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant: Complete Statistical AnalysisIndependent statistical analysis of Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults: Complete Statistical AnalysisIndependent statistical analysis of Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults: primary endpoint results, effect estimate with confidence…
- Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases: Complete Statistical AnalysisIndependent statistical analysis of Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- DOPAACRO 002Independent statistical analysis of Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study: Complete Statistical AnalysisIndependent statistical analysis of Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…